A mutated CCR5 gene may have favorable prognostic implications in MS
A mutated CCR5 gene may have favorable prognostic implications in MS
复制标题
DOI：
10.1212/01.wnl.0000069921.20347.9e
复制
发表时间：
2003-07-22
期刊：
影响因子：
9.9
通讯作者：
Achiron, A
中科院分区：
文献类型：
--
作者：
Kantor, R;Bakhanashvili, M;Achiron, A
作者在256例多发性硬化症(MS)患者中调查了趋化因子受体CCR5的突变等位基因Delta32CCR5与疾病进展的关系。研究队列中突变的等位基因频率为7.4%，与以色列普通人群的报告相似。与携带CCR5野生型的MS患者相比，Delta32CCR5纯合子和杂合子患者的残疾进展时间延长(p<；0.005)。CCR5等位基因突变可能被认为是MS的一个有利的预后因素。
The authors investigated the association between Delta32CCR5, a mutated allele of the chemokine receptor CCR5, and disease progression in 256 patients with multiple sclerosis ( MS). The mutated allele frequency in the study cohort was 7.4%, similar to that reported in the general Israeli population. Progression to disability was prolonged in Delta32CCR5 homozygotes and heterozygotes compared with MS patients with the CCR5 wild-type genotype ( p < 0.005). Mutated CCR5 allele may be considered a favorable prognostic factor in MS.